Svetlana V. Dora

Svetlana V. Dora

Auto-generated profile, based on publicly available information

Svetlana V. Dora

Pavlov First Saint Petersburg State Medical University

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2017 in Clinical and experimental thyroidology
Verified
Journal Article
Open access
PDF file
DSDarya E. Soboleva
Darya E. Soboleva
SDSvetlana V. Dora
Svetlana V. Dora
TKTatiana Karonova
Tatiana Karonova
AVAnna R. Volkova
Anna R. Volkova
EGElena Grineva
Elena Grineva
Обоснование. В мире около двух миллиардов человек имеют недостаточное потребление йода. Цель. Оценить обеспеченность йодом и эффективность профилактики йодного дефицита у взрослого населения Санкт-Петербурга. Методы. В ретроспективной части работы проведен анализ распространенности гипертиреотропинемии новорожденных Санкт-Петербурга за период 2013–2014 гг. В одномоментное поперечное когортное исследование были включены 542 жителя Санкт-Петербурга в возрасте 18–77 лет. Все участники были разделены на три группы согласно возрасту. Беременные женщины были выделены в отдельную группу. У всех участников проведено анкетирование и проанализированы значения йодурии. Результаты. Количество новорожденных, имевших концентрацию тиреотропного гормона более 5 мЕД/л, составило 6,9%, отражая дефицит йода легкой степени тяжести у населения. Йодированную соль использовали в пищу только 41,1% всех обследованных и 52,2% беременных женщин. Препараты йода принимала половина беременных женщин. Медиана йодурии (МЙУ) всех участников составила 91,2 мкг/л и соответствовала дефициту йода легкой степени тяжести. Значение МЙУ у беременных женщин составило 112,4 мкг/л и соответствовало недостаточному потреблению йода. Заключение. Население Санкт-Петербурга проживает в регионе легкого дефицита йода. Профилактика дефицита йода, проводимая в Санкт-Петербурге в 2013–2015 гг., недостаточно эффективна. Лица репродуктивного возраста и беременные женщины имеют дефицит йода легкой степени тяжести.

3 May 2023 in Endocrine Surgery
Verified
Journal Article
Open access
PDF file
GSG. V. Semikova
G. V. Semikova
SDS. V. Dora
S. V. Dora
ZSZ. V. Shvets
Z. V. Shvets
EKE. A. Kulchitskaya
E. A. Kulchitskaya
AVA. R. Volkova
A. R. Volkova
BACKGROUND: Obesity is associated with development of menstrual disorders (MD), a decrease in ovarian reserve and infertility. Treatment of obesity contributes to the normalization of the reproductive function of women. Bariatric surgery is known to be the most effective method of obesity treatment, while the most common intervention is the sleeve gastrectomy (SG), the effect of which on menstrual function and ovarian reserve has not been studied enough.AIM: To study the effect of SG on menstrual function and ovarian reserve in obese women of reproductive ageMATERIALS AND METHODS: Female patients with BMI ≥ 35 kg/m2 aged 25 to 36 years were examined. At baseline and 6 months after SG, the characteristics of menstrual function were determined, BMI and HOMA-IR were calculated, and the level of anti-Müllerian hormone (AMH) was measured. The obtained parameters were compared in patients with and without MDRESULTS: . In all patients, 6 months after SG, there was a decrease in BMI: 30.1 kg/m2 (29.3–32.1) and 39.3 kg/m2 (37.3–41.0) (p<0.001), HOMA -IR: 5.0 (4.1–5.9) and 2.8 (2.1–3.2) (p=0.001). The initial level of AMH in patients with MD (n=12) was lower than in patients with normal menstrual function (n=10): 2.4 ng/ml (1.9–2.0) and 3.2 ng/ml (2.6–4.2), respectively (p=0.032). A significant increase in AMH levels occurred only in the group of patients with MD (p=0.04). MD remained only in 3 women.CONCLUSION: SG in patients of reproductive age with obesity is associated with the normalization of menstrual function and an increase in AMH, as well as a decrease in the degree of insulin resistance.

10 May 2026 in Obstetrics, Gynecology and Reproduction
Verified
Journal Article
Closed access
ZSZ. V. Shvets
Z. V. Shvets
SDS. V. Dora
S. V. Dora
YKYu. Sh. Khalimov
Yu. Sh. Khalimov
ALA. V. Lisker
A. V. Lisker
AKA. B. Kolyabina
A. B. Kolyabina
Aim: to evaluate an effect of laparoscopic sleeve gastrectomy (LSG) on fertility in obese reproductive age women and to identify factors associated with subsequent pregnancy. Materials and Methods. This single-center observational retrospective comparative study included 48 women aged 25–36 years who underwent LSG. Body mass index (BMI), insulin resistance index HOMA-IR (Homeostasis Model Assessment of Insulin Resistance), anti-Müllerian hormone (AMH), and antral follicle count (AFC) were assessed before and 12 months post-surgery. Smoking history, family history of premature menopause, and prior ovarian surgery were analyzed. After 3 years post-surgery, patients planning pregnancy were stratified as follows: Group 1 – achieved pregnancy (n = 16, including 10 spontaneous and 6 through assisted reproductive technologies), Group 2 – no pregnancy (n = 14). Results. Following LSG, significant reductions were observed in BMI (from 44.2 to 31.3 kg/m2; p = 0.001) and HOMA-IR index (from 8.3 to 5.1; p = 0.001). Pregnancy occurred in 53.3 % of patients. Women who did not conceive had higher baseline BMI (47.1 kg/m2 vs. 41.5 kg/m2; p = 0.025), HOMA-IR index (10.2 vs. 5.8; p = 0.005), and more pronounced decline in ovarian reserve post-LSG: AMG level was 0.89 vs. 2.65 ng/ml (p = 0.001). Significant risk factors included familial history of premature menopause (85.7 %), ovarian surgery (42.9 %), and smoking (78.6 %). Correlation analysis revealed significant negative associations between pregnancy likelihood and baseline BMI (r = –0.42; p = 0.02) and HOMA-IR (r = –0.52; p = 0.003), whereas AFC showed positive correlation (r = 0.38; p = 0.04). Statistically significant associations were found between pregnancy and smoking (p = 0.02), prior ovarian surgery (p = 0.02), and familial history of early menopause (p = 0.04). Conclusion. LSG use was associated with improved metabolic parameters and fertility recovery in 53.3 % of patients. However, given the small sample size, these findings require validation in larger-scale cohorts. The likelihood of achieving pregnancy depends on a complex interplay between the examined factors, underscoring a need for individualized risk assessment and a personalized approach to therapy.

1 January 2025 in Therapist’s Bulletin
Verified
Journal Article
Closed access
MZM.V. Zimina
M.V. Zimina
RPRussian Federation Saint Petersburg
Russian Federation Saint Petersburg
SDS.V. Dora
S.V. Dora
YKYu.SH. Khalimov
Yu.SH. Khalimov
ALA.V. Lisker
A.V. Lisker
AMA.SH. Mamedova
A.SH. Mamedova
Aim. To investigate the association between premature ovarian insufficiency (POI) and the development of metabolic syndrome in women. Design. A single-center, cross-sectional comparative study. Materials and methods. The study included 80 women divided into three groups: Group 1 (control, n = 39) — women with regular menstrual cycles and normal levels of follicle-stimulating hormone (FSH) and estradiol; Group 2 (n = 24) — women with amenorrhea lasting 3–12 months and elevated FSH > 25 IU/L (POI); Group 3 (n = 17) — women with amenorrhea lasting > 12 months and persistently elevated FSH (premature menopause, PM). Anthropometric parameters, blood pressure, and laboratory markers of carbohydrate and lipid metabolism were analyzed. Results. Women with estrogen deficiency (Groups 2 and 3) exhibited significantly higher body mass index, waist circumference, systolic and diastolic blood pressure, and adverse changes in lipid profile, including decreased high-density lipoprotein, elevated low-density lipoprotein, and triglycerides. Additionally, a considerable proportion of PM patients showed impaired fasting glucose, indicating a high risk of insulin resistance and type 2 diabetes. The prevalence of metabolic syndrome (based on IDF criteria) was 47.6% in the POI group and 52.9% in the PM group. Conclusion. Premature ovarian insufficiency and premature menopause are associated with significant metabolic disturbances, including abdominal obesity, hypertension, dyslipidemia, and impaired glucose metabolism. These conditions represent independent risk factors for metabolic syndrome in young women. Early diagnosis and prevention of metabolic complications in this patient population are of crucial clinical importance. Large-scale multicenter studies are needed to validate these findings. Keywords: premature ovarian insufficiency, premature menopause, metabolic syndrome, abdominal obesity, hypoestrogenism.

1 January 2020 in Endocrinology: News, Opinions, Training
Verified
Journal Article
Closed access
AVA.R. Volkova
A.R. Volkova
EOE.N. Ostroukhova
E.N. Ostroukhova
SDS.V. Dora
S.V. Dora
KVK.A. Vlasova
K.A. Vlasova
GSG.V. Semikova
G.V. Semikova
AFAcademician I. P. Pavlov First St. Petersburg State Medical University of the Ministry of Healthcare of the Russian Federation"
Academician I. P. Pavlov First St. Petersburg State Medical University of the Ministry of Healthcare of the Russian Federation"
Sheehan syndrome in a patient with thyroid disease

26 July 2026 in Nephrology (Saint-Petersburg)
Verified
Journal Article
Closed access
PDF file
YHYu. Sh. Halimov
Yu. Sh. Halimov
SDS. V. Dora
S. V. Dora
ALA. V. Lisker
A. V. Lisker
Ekaterina PolyakovaEkaterina Polyakova
Ekaterina Polyakova
ICI. V. Cherebillo
I. V. Cherebillo
ПГП. В. Гинзбург
П. В. Гинзбург
BACKGROUND. Chronic kidney disease (CKD) is a persistent disorder of kidney structure or function lasting more than three months, with diabetes mellitus being one of its leading causes worldwide. Since 2023, finerenone a nonsteroidal mineralocorticoid receptor antagonist (MRA) has been approved in the Russian Federation. Preclinical and clinical studies have demonstrated its anti-inflammatory and antifibrotic effects, positioning finerenone as a promising treatment for patients with type 2 diabetes mellitus (T2DM) and CKD. While initial data from scientific literature show encouraging results, further research is needed to better understand its mechanism of action and evaluate long-term outcomes. THE AIM: to evaluation of the efficacy and safety of finerenone in patients with type 2 diabetes mellitus and chronic kidney disease. PATIENTS AND METHODS . As part of a clinical observation study, 25 patients with comorbid type 2 diabetes mellitus and chronic kidney disease were evaluated. All participants underwent comprehensive testing, including the assessments of biochemical parameters of kidney function, carbohydrate metabolism and lipid profile. Finerenone was used as an adjunctive therapy. A follow-up evaluation was performed after 6 months of therapy. Statistical analysis was performed using specialized software employing parametric or nonparametric methods, depending on the nature of the data distribution. The critical significance level of p < 0.05. RESULTS. The study included 25 patients with type 2 diabetes mellitus and chronic kidney disease (mean age 60.28 ± 6.90 years, comprising 15 were men (60 %) and 10 were women (40 %). After six months of finerenone therapy, significant reductions in albuminuria (219→158 mg/g, p<0.001) and improvements in GFR (56.2→59.8 ml/min, p<0.001) were observed. Normalization of albuminuria was registered in 12 % of patients. Regarding the safety of use, a decrease in cardiovascular risk was noted 32 % to 16 %. CONCLUSIONS. In patients with diabetic nephropathy, finerenone demonstrates significant nephroprotective effects, as evidenced by redused in albuminuria (p<0.0001) and improved glomerular filtration rates. The drug also exhibits a favorable safety profile with no clinically significant impact on electrolyte balance (p<0.05). Of particular interest is the demonstrated decrease in the proportion of patients at high cardiovascular risk (from 32 % to 16 %). These findings support the inclusion of finerenone in combination therapy regimens for diabetic kidney disease.